Skip Navigation LinksHome > August 2014 - Volume 32 - Issue 8 > Chymase inhibition improves vascular dysfunction and surviva...
Journal of Hypertension:
doi: 10.1097/HJH.0000000000000231
ORIGINAL PAPERS: Pathophysiological aspects

Chymase inhibition improves vascular dysfunction and survival in stroke-prone spontaneously hypertensive rats

Takai, Shinjia; Jin, Denana; Chen, Hongb; Li, Wenc; Yamamoto, Hideyukic; Yamanishi, Kyosukec; Miyazaki, Mizuoa; Higashino, Hideakid; Yamanishi, Hiromichid; Okamura, Harukic

Collapse Box

Abstract

Objective: To clarify the role of chymase in hypertension, we evaluated the effect of a chymase inhibitor, TY-51469, on vascular dysfunction and survival in stroke-prone spontaneously hypertensive rats (SHR-SP).

Methods: SHR-SP were treated with TY-51469 (1 mg/kg per day) or placebo from 4 to 12 weeks old or until death. Wistar–Kyoto rats were used as a normal group.

Results: SBP was significantly higher in both the placebo and TY-51469 groups than in the normal group, but there was no significant difference between the two treatment groups. Plasma renin, angiotensin-converting enzyme activity and angiotensin II levels were not different between the placebo and TY-51469 groups. In contrast, vascular chymase-like activity was significantly higher in the placebo than in the normal group, but it was reduced by TY-51469. Acetylcholine-induced vascular relaxation was significantly higher in the TY-51469 group than in the placebo group. There was significant augmentation of the number of monocytes/macrophages and matrix metalloproteinase-9 activity in aortic tissue from the placebo group compared with the normal group, and these changes were attenuated by TY-51469. There were also significant increases in mRNA levels of monocyte chemoattractant protein-1 and tumor necrosis factor-α in the placebo group that were attenuated by TY-51469. Cumulative survival was significantly prolonged in the TY-51469 group compared with the placebo group.

Conclusion: Chymase might play an important role in vascular dysfunction via augmentation both of matrix metalloproteinase-9 activity and monocyte/macrophage accumulation in SHR-SP, and its inhibition may be useful for preventing vascular remodeling and prolonging survival.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins

Login

Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.